Professional
Added to YB: 2024-10-22
Pitch date: 2024-10-18
BGNE [bullish]
BeOne Medicines AG
+45.03%
current return
Author Info
No bio for this author
Company Info
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Market Cap
$40.5B
Pitch Price
$220.00
Price Target
288.93 (-9%)
Dividend
N/A
EV/EBITDA
108.94
P/E
625.64
EV/Sales
7.53
Sector
Biotechnology
Category
growth
BeiGene (BGNE US) – Sales exceeding expectations and achieving non-GAAP profitability
BGNE BUY: TP $288.93 (30% upside). Q2 product sales $921M (+23% QoQ, +66% YoY). Zanubrutinib $637M (+30% QoQ, +107% YoY), 24% BTKi market share. Non-GAAP profit $48M in Q2. Expect breakeven FY25. Sonrotoclax potential blockbuster. CDK4 inhibitor data Dec 2024. Strong pipeline.
Read full article (2 min)